Research programme: tubulin binders - Novuspharma
Alternative Names: Tubulin binders research programme - NovuspharmaLatest Information Update: 07 Jan 2004
At a glance
- Originator Novuspharma
- Class
- Mechanism of Action Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Colorectal cancer
Most Recent Events
- 07 Jan 2004 Novuspharma has since merged with and into the US company Cell Therapeutics
- 08 Sep 2003 Discontinued - Preclinical for Colorectal cancer in Italy (unspecified route)
- 24 Oct 2001 Preclinical development for Colorectal cancer in Italy (Unknown route)